Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
___	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Abdominal	O
distension,	O
weight	B-Weight_loss
loss	B-Weight_loss
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Omental	O
Biopsy	O
Parcentesis	O
x2	O
History	O
of	O
Present	O
Illness:	O
Ms.	O
___	O
is	O
a	O
___	O
year	O
old	O
female	O
with	O
a	O
PMHx	O
of	O
hypertension	O
who	O
presents	O
with	O
urinary	O
retention.	O
The	O
patient	O
has	O
multiple	O
complaints	O
and	O
it	O
is	O
difficult	O
to	O
get	O
a	O
complete	O
picture	O
of	O
what	O
has	O
been	O
going	O
on	O
the	O
last	O
few	O
days.	O
She	O
apparently	O
went	O
2	O
days	O
without	O
being	O
able	O
to	O
urinate.	O
She	O
also	O
had	O
severe	O
worsening	O
of	O
her	O
chronic	O
back	O
period	O
over	O
that	O
time.	O
Additionally,	O
she	O
reports	O
trouble	O
breathing	O
for	O
a	O
couple	O
of	O
days,	O
abdominal	O
pain	O
for	O
several	O
days	O
(down	O
the	O
middle	O
of	O
her	O
abdomen,	O
not	O
worse	O
with	O
food),	O
abdominal	O
swelling	O
for	O
a	O
couple	O
of	O
months,	O
weakness	O
in	O
her	O
arms	O
and	O
legs,	O
fever,	O
a	O
55	O
lb	O
weight	B-Weight_loss
loss	B-Weight_loss
in	O
the	O
past	O
1	O
month	O
(though	O
normal	O
appetite),	O
and	O
says	O
that	O
she	O
has	O
fibroids	O
in	O
her	O
uterus,	O
a	O
tumor	O
in	O
her	O
pancreas,	O
and	O
her	O
"bladder	O
fell	O
out."	O
She	O
also	O
complains	O
of	O
her	O
colon	O
being	O
blocked.	O
She	O
was	O
taken	O
to	O
___	O
before	O
being	O
transferred	O
to	O
___.	O
She	O
had	O
a	O
CT	O
abdomen/pelvis	O
which	O
showed	O
a	O
septated	O
pelvic	O
mass	O
which	O
had	O
increased	O
in	O
size,	O
new	O
extensive	O
ascites,	O
new	O
vaginal	O
prolapse,	O
new	O
bilateral	O
hydronephrosis,	O
a	O
poorly	O
defined	O
mass	O
in	O
the	O
pancreatic	O
body	O
and	O
tail,	O
and	O
a	O
hypodensity	O
in	O
the	O
liver.	O
A	O
Foley	O
catheter	O
was	O
placed.	O
Blood	O
and	O
urine	O
cultures	O
were	O
sent.	O
Her	O
WBC	O
was	O
22.4	O
(previously	O
___	O
per	O
OSH	O
records).	O
Her	O
Cr	O
was	O
1.2	O
(baseline	O
0.8-1).	O
She	O
was	O
given	O
vancomycin	O
and	O
Zosyn	O
prior	O
to	O
transfer.	O
In	O
the	O
___	O
ED,	O
her	O
initial	O
vitals	O
were	O
T	O
98.8	O
(Tmax	O
102.4),	O
HR	O
115,	O
BP	O
104/95,	O
RR	O
24,	O
O2	O
97%	O
on	O
3L.	O
Her	O
labs	O
were	O
notable	O
for	O
a	O
WBC	O
31.2,	O
INR	O
1.8,	O
Cr	O
1.3,	O
lactate	O
1.8,	O
Lipase	O
258,	O
Alb	O
2.8,	O
UA	O
with	O
>	O
182	O
RBCs,	O
114	O
WBCs,	O
1	O
Epi,	O
+Nitrites.	O
Given	O
urinary	O
retention	O
and	O
back	O
pain,	O
a	O
code	O
cord	O
was	O
called.	O
An	O
MRI	O
did	O
not	O
show	O
evidence	O
of	O
cord	O
or	O
cauda	O
equina	O
compression.	O
A	O
CXR	O
was	O
unremarkable.	O
The	O
patient	O
was	O
given	O
1L	O
NS	O
and	O
Zosyn.	O
OB/GYN	O
was	O
consulted	O
and	O
recommended	O
admission	O
to	O
medicine	O
for	O
sepsis.	O
ROS:	O
Pertinent	O
positives	O
and	O
negatives	O
as	O
noted	O
in	O
the	O
HPI.	O
Otherwise	O
a	O
10-point	O
ROS	O
was	O
reviewed	O
and	O
is	O
negative.	O
DATA:	O
I	O
have	O
reviewed	O
the	O
relevant	O
labs,	O
radiology	O
studies,	O
tracings,	O
and	O
medical	O
records.	O
Notable	O
findings	O
are	O
given	O
below	O
in	O
the	O
assessment	O
and	O
plan	O
or	O
in	O
the	O
HPI.	O
SUMMARY/ASSESSMENT:	O
Ms.	O
___	O
is	O
a	O
___	O
female	O
with	O
a	O
past	O
medical	O
history	O
of	O
hypertension	O
and	O
a	O
large	O
pelvic	O
mass	O
who	O
presents	O
with	O
acute	O
urinary	O
retention	O
and	O
sepsis	O
likely	O
from	O
a	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection.	B-Urinary_tract_infection
Past	O
Medical	O
History:	O
-Hypertension	O
-Type	O
2	O
Diabetes	O
(no	O
longer	O
requiring	O
medication)	O
-HLD	O
-Schizoaffective	O
disorder	O
-Vertigo	O
-Constipation	I-Constipation
-HCV	O
-IBS	O
-Pancreatic	O
mass	O
-Adjustment	O
disorder	O
with	O
anxiety	O
-Breast	O
abscess	O
Social	O
History:	O
___	O
Family	O
History:	O
Mother	O
with	O
TB,	O
father	O
with	O
still	O
alive	O
Physical	O
Exam:	O
ADMISSION	O
EXAM:	O
VITALS:	O
___	O
0305	O
Temp:	O
97.5	O
PO	O
BP:	O
101/62	O
HR:	O
64	O
RR:	O
20	O
O2	O
sat:	O
93%	O
O2	O
delivery:	O
2L	O
GENERAL:	O
Alert	O
and	O
in	O
no	O
apparent	O
distress;	O
cachectic	B-Malnutrition
EYES:	O
Anicteric,	O
no	O
conjunctival	O
injection,	O
pupils	O
equally	O
round	O
ENT:	O
Ears	O
and	O
nose	O
without	O
visible	O
erythema,	O
masses,	O
or	O
trauma.	O
Oropharynx	O
without	O
visible	O
lesions,	O
erythema	O
or	O
exudate.	O
CV:	O
Heart	O
regular,	O
no	O
murmur,	O
no	O
S3,	O
no	O
S4.	O
RESP:	O
Lungs	O
clear	O
to	O
auscultation	O
with	O
good	O
air	O
movement	O
bilaterally.	O
Breathing	O
is	O
non-labored	O
GI:	O
Abdomen	O
soft,	O
mild	O
tenderness	O
down	O
the	O
middle	O
of	O
the	O
abdomen,	O
distended.	O
No	O
rebound	O
or	O
guarding.	O
GU:	O
Foley	O
in	O
place.	O
MSK:	O
Moves	O
all	O
extremities,	O
thin,	O
warm	O
and	O
well	O
perfused,	O
no	O
edema.	O
SKIN:	O
No	O
rashes	O
or	O
ulcerations	O
noted.	O
NEURO:	O
Alert,	O
oriented,	B-Delirium
face	O
symmetric,	O
gaze	O
conjugate	O
with	O
EOM,	O
speech	O
fluent,	O
moves	O
all	O
limbs	O
PSYCH:	O
pleasant,	O
appropriate	O
mood	O
and	O
affect	O
Pertinent	O
Results:	O
Admission	O
Labs	O
___	O
05:50PM	O
BLOOD	O
WBC-31.2*	O
RBC-4.52	O
Hgb-12.8	O
Hct-38.3	O
MCV-85	O
MCH-28.3	O
MCHC-33.4	O
RDW-16.2*	O
RDWSD-50.0*	O
Plt	O
___	O
___	O
05:50PM	O
BLOOD	O
___	O
PTT-28.2	O
___	O
___	O
05:50PM	O
BLOOD	O
Glucose-132*	O
UreaN-31*	O
Creat-1.3*	O
Na-136	O
K-4.0	O
Cl-103	O
HCO3-16*	O
AnGap-17	O
___	O
05:50PM	O
BLOOD	O
Albumin-2.8*	O
Calcium-8.7	O
Phos-3.6	O
Mg-1.9	O
___	O
06:23AM	O
BLOOD	O
%HbA1c-6.1*	O
eAG-128*	O
___	O
05:17AM	O
BLOOD	O
CEA-19.4*	O
CA125-48*	O
URINE	O
CULTURE	O
(Final	O
___:	O
ESCHERICHIA	O
COLI.	O
>100,000	O
CFU/mL.	O
PRESUMPTIVE	O
IDENTIFICATION.	O
Cefazolin	O
interpretative	O
criteria	O
are	O
based	O
on	O
a	O
dosage	O
regimen	O
of	O
2g	O
every	O
8h.	O
YEAST.	O
10,000-100,000	O
CFU/mL.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
ESCHERICHIA	O
COLI	O
|	O
AMPICILLIN------------	O
4	O
S	O
AMPICILLIN/SULBACTAM--	O
4	O
S	O
CEFAZOLIN-------------	O
<=4	O
S	O
CEFEPIME--------------	O
<=1	O
S	O
CEFTAZIDIME-----------	O
<=1	O
S	O
CEFTRIAXONE-----------	O
<=1	O
S	O
CIPROFLOXACIN---------<=0.25	O
S	O
GENTAMICIN------------	O
<=1	O
S	O
MEROPENEM-------------<=0.25	O
S	O
NITROFURANTOIN--------	O
<=16	O
S	O
PIPERACILLIN/TAZO-----	O
<=4	O
S	O
TOBRAMYCIN------------	O
<=1	O
S	O
TRIMETHOPRIM/SULFA----	O
<=1	O
S	O
Blood	O
Culture,	O
Routine	O
(Final	O
___:	O
ESCHERICHIA	O
COLI.	O
FINAL	O
SENSITIVITIES.	O
Cefazolin	O
interpretative	O
criteria	O
are	O
based	O
on	O
a	O
dosage	O
regimen	O
of	O
2g	O
every	O
8h.	O
ESCHERICHIA	O
COLI.	O
___	O
MORPHOLOGY.	O
FINAL	O
SENSITIVITIES.	O
Cefazolin	O
interpretative	O
criteria	O
are	O
based	O
on	O
a	O
dosage	O
regimen	O
of	O
2g	O
every	O
8h.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
ESCHERICHIA	O
COLI	O
|	O
ESCHERICHIA	O
COLI	O
|	O
|	O
AMPICILLIN------------	O
4	O
S	O
8	O
S	O
AMPICILLIN/SULBACTAM--	O
4	O
S	O
<=2	O
S	O
CEFAZOLIN-------------	O
<=4	O
S	O
<=4	O
S	O
CEFEPIME--------------	O
<=1	O
S	O
<=1	O
S	O
CEFTAZIDIME-----------	O
<=1	O
S	O
<=1	O
S	O
CEFTRIAXONE-----------	O
<=1	O
S	O
<=1	O
S	O
CIPROFLOXACIN---------<=0.25	O
S	O
<=0.25	O
S	O
GENTAMICIN------------	O
<=1	O
S	O
<=1	O
S	O
MEROPENEM-------------<=0.25	O
S	O
<=0.25	O
S	O
PIPERACILLIN/TAZO-----	O
<=4	O
S	O
<=4	O
S	O
TOBRAMYCIN------------	O
<=1	O
S	O
<=1	O
S	O
TRIMETHOPRIM/SULFA----	O
<=1	O
S	O
<=1	O
S	O
___	O
Blood	O
culture	O
NGTD	O
#	O
CXR	O
(___):	O
No	O
definite	O
acute	O
cardiopulmonary	O
process.	O
#	O
MRI	O
Spine	O
(___):	O
.	O
No	O
evidence	O
for	O
epidural	O
mass,	O
collection,	O
or	O
abscess	O
within	O
limitations	O
of	O
a	O
noncontrast	O
examination.	O
2.	O
Multilevel	O
degenerative	O
changes	O
within	O
the	O
cervical	O
spine	O
are	O
noted,	O
most	O
prominent	O
at	O
C4-C5	O
with	O
moderate	O
canal	O
narrowing,	O
moderate	O
severe	O
left	O
and	O
moderate	O
right	O
neural	O
foraminal	O
narrowing.	O
3.	O
Multilevel	O
degenerative	O
changes	O
within	O
the	O
lumbar	O
spine	O
are	O
also	O
noted,	O
detailed	O
above	O
and	O
without	O
moderate/severe	O
canal	O
narrowing.	O
4.	O
Subcentimeter	O
T2	O
hypointense	O
right	O
renal	O
cortical	O
lesion,	O
which	O
may	O
reflect	O
a	O
hemorrhagic	O
cyst	O
but	O
is	O
incompletely	O
characterized.	O
Initial	O
evaluation	O
by	O
ultrasound	O
could	O
be	O
considered	O
if	O
clinically	O
indicated.	O
5.	O
Large	O
volume	O
ascites	O
and	O
a	O
small	O
to	O
moderate	O
right	O
pleural	O
effusion	O
with	O
adjacent	O
atelectasis.	O
.	O
#	O
Abd/pelvic	O
CTA	O
(___):	O
1.	O
Locally	O
invasive	O
pancreatic	O
mass	O
in	O
the	O
body	O
and	O
tail	O
of	O
the	O
pancreas	O
encasing	O
multiple	O
vessels	O
(splenic	O
artery,	O
SMA,	O
celiac	O
trunk,	O
proximal	O
common	O
hepatic	O
artery,	O
SMV	O
at	O
the	O
porta	O
hepatis	O
confluence)	O
and	O
invades	O
the	O
retroperitoneum	O
involving	O
the	O
left	O
adrenal	O
gland.	O
Omental	O
caking	O
and	O
peritoneal	O
carcinomatosis	O
with	O
malignant	O
ascites.	O
2.	O
Large	O
multi-septated	O
pelvic	O
mass	O
could	O
represent	O
pseudomyxoma,	O
ovarian	O
primary	O
or	O
metastatic	O
malignancy	O
or	O
primary	O
peritoneal	O
malignancy.	O
3.	O
Stable	O
prominence	O
of	O
the	O
renal	O
excretory	O
system	O
bilaterally.	O
4.	O
Interval	O
development	O
of	O
compressive	O
subsegmental	O
atelectasis	O
at	O
both	O
bases	O
of	O
the	O
lungs,	O
likely	O
secondary	O
to	O
ascites.	O
#	O
Peritoneal	O
fluid	O
(___):	O
cytology	O
negative	O
#	O
Therapeutic	O
paracentesis	O
(___):	O
1.	O
Technically	O
successful	O
ultrasound	O
guided	O
diagnostic	O
and	O
therapeutic	O
paracentesis.	O
2.	O
5	O
L	O
of	O
fluid	O
were	O
removed.	O
Cytology	O
negative	O
for	O
malignancy	O
.	O
#	O
U/S	O
guided	O
omental	O
biopsy	O
(___):	O
Technically	O
successful	O
ultrasound-guided	O
core	O
needle	O
biopsy	O
of	O
an	O
omental	O
plaque	O
in	O
the	O
right	O
mid	O
abdomen.	O
PATH:	O
no	O
malignant	O
cell,	O
adipose	O
tissue	O
#	O
EUS	O
(___):	O
Attempted	O
but	O
food	O
in	O
stomach	O
#	O
EUS	O
bx	O
(___):	O
(Prelim)	O
pancreatic	O
mass	O
supplanting	O
pancreatic	O
body/tail.	O
Encasement	O
of	O
multiple	O
vessels	O
with	O
thrombus	O
vs.	O
tumor	O
extension	O
into	O
portal	O
vein.	O
Mult	O
bxs	O
obtained.	O
#	O
Therapeutic	O
paracentesis	O
(___):	O
3.5	O
L.	O
Brief	O
Hospital	O
Course:	O
This	O
is	O
a	O
___	O
year	O
old	O
female	O
admitted	O
___	O
with	O
sepsis	O
secondary	O
to	O
Ecoli	O
bacteremia,	O
found	O
to	O
have	O
urinary	O
retention,	O
imaging	O
also	O
notable	O
for	O
new	O
pancreatic	O
mass,	O
several	O
pelvic	O
masses,	O
concerning	O
new	O
diagnosis	O
of	O
malignancy	O
versus	O
malignancies,	O
now	O
undergoing	O
workup	O
#	O
Ecoli	O
Sepsis	O
secondary	O
#	O
Ecoli	O
Acute	O
blood	O
stream	O
infection	O
#	O
Ecoli	O
UTI	B-Urinary_tract_infection
Admitted	O
with	O
positive	O
blood	O
cultures	O
showing	O
Ecoli,	O
pan-sensitive.	O
He	O
was	O
treated	O
with	O
IV	O
ceftriaxone,	O
and	O
then	O
when	O
clinically	O
stable	O
transitioned	O
to	O
PO	O
cipro	O
to	O
complete	O
a	O
14	O
day	O
course	O
for	O
bacteremia	O
course	O
(last	O
day	O
___.	O
#	O
Cancer	O
of	O
unknown	O
origin	O
#	O
Malignancy	O
of	O
pancreas	O
#	O
Malignant	O
Ascites	O
Presenting	O
for	O
a	O
second	O
opinion	O
after	O
both	O
___	O
and	O
___	O
told	O
her	O
she	O
had	O
likely	O
cancer.	O
On	O
admission	O
oncology	O
was	O
consulted	O
and	O
recommended	O
a	O
CTA	O
pancreas	O
protocol.	O
This	O
showed	O
a	O
locally	O
invasive	O
pancreatic	O
tail	O
mass	O
that	O
was	O
invading	O
many	O
blood	O
vessels.	O
She	O
was	O
also	O
found	O
to	O
have	O
multiple	O
areas	O
of	O
likely	O
metastatic	O
disease.	O
Given	O
multiple	O
masses	O
in	O
abdomen,	O
it	O
was	O
unclear	O
if	O
there	O
was	O
a	O
single	O
malignancy	O
vs	O
a	O
second	O
malignancy,	O
prompting	O
recommendation	O
for	O
additional	O
workup	O
with	O
pathology/cytology.	O
Given	O
negative	O
peritoneal	O
fluid	O
cytology	O
x	O
2,	O
she	O
two	O
underwent	O
an	O
omental	O
biopsy	O
___	O
which	O
was	O
non-diagnostic.	O
Ultimately,	O
given	O
the	O
large	O
pancreatic	O
mass	O
in	O
the	O
body/tail,	O
the	O
decision	O
was	O
to	O
proceed	O
with	O
an	O
EUS	O
with	O
biopsy	O
on	O
___.	O
She	O
underwent	O
the	O
procedure	O
without	O
complication,	O
but	O
the	O
final	O
path,	O
again,	O
was	O
non-diagnostic.	O
The	O
pancreatic	O
mass	O
is	O
largely	O
necrotic	O
and	O
thus	O
getting	O
a	O
solid	O
sample	O
can	O
be	O
technically	O
difficult.	O
After	O
much	O
discussion,	O
it	O
was	O
decided	O
to	O
repeat	O
the	O
EUS/bx	O
as	O
an	O
outpt.	O
She	O
was	O
informed	O
that	O
the	O
risk	O
of	O
pancreatic	O
cancer	O
is	O
really	O
high,	O
given	O
the	O
appearance	O
of	O
the	O
pancreatic	O
mass,	O
the	O
invasion	O
of	O
adjacent	O
vessels,	O
elevated	O
___	O
and	O
exudative	O
peritoneal	O
fluid	O
collection.	O
It	O
is	O
unclear	O
how	O
much	O
she	O
absorbed	O
this	O
information	O
and	O
focused	O
on	O
the	O
getting	O
a	O
hysterectomy	O
for	O
the	O
large	O
pelvic	O
mass.	O
However,	O
she	O
understood	O
that	O
no	O
surgical	O
procedure	O
or	O
chemotherapy	O
is	O
possible	O
without	O
a	O
tissue	O
diagnosis.	O
She	O
will	O
return	O
for	O
this	O
procedure	O
as	O
an	O
outpt.	O
At	O
the	O
present,	O
pancreatic	O
CA	O
remains	O
highest	O
on	O
the	O
differential,	O
although	O
it	O
is	O
unclear	O
if	O
diagnosis	O
of	O
single	O
malignancy	O
(e.g.	O
pancreatic)	O
vs	O
2	O
new	O
malignancies	O
(e.g.	O
pancreatic	O
+	O
another	O
cell	O
origin	O
involving	O
the	O
Ovaries).	O
#	O
Bladder	O
Neck	O
Obstruction	O
On	O
admission	O
patient	O
was	O
found	O
to	O
have	O
bilateral	O
hydronephrosis.	O
This	O
was	O
suspected	O
to	O
relate	O
to	O
pelvic	O
mass	O
obstructing	O
the	O
bladder	O
neck.	O
Patient	O
had	O
a	O
foley	O
placed	O
with	O
improvement	O
in	O
hydronephrosis.	O
#	O
Cancer-related	O
pain	O
Patient	O
had	O
abdominal	O
pain	O
related	O
to	O
multiple	O
masses	O
and	O
ascites.	O
Patient	O
was	O
seen	O
by	O
palliative	O
care	O
and	O
started	O
on	O
oxycodone	O
with	O
improvement	O
in	O
symptoms.	O
#	O
Social	O
issues	O
Complex	O
situation	O
previously	O
outlined	O
by	O
Dr.	O
___.	O
During	O
the	O
hospital	O
stay,	O
it	O
was	O
not	O
clear	O
whether	O
she	O
understood	O
the	O
gravity	O
of	O
her	O
situation.	O
She	O
expressed	O
desire	O
to	O
go	O
home	O
after	O
the	O
hospitalization,	O
and	O
initially	O
she	O
was	O
deemed	O
unsafe	O
for	O
discharge.	O
However,	O
she	O
was	O
able	O
to	O
ambulate	O
via	O
walker	B-Mobile_with_aid
and	O
she	O
was	O
ultimately	O
cleared	O
by	O
___.	O
She	O
appeared	O
at	O
the	O
time	O
of	O
discharge,	O
to	O
absorb	O
her	O
situation,	O
the	O
high	O
suspicion	O
for	O
cancer	O
-	O
and	O
to	O
have	O
capacity	O
to	O
make	O
medical	O
decision.	O
She	O
does	O
have	O
a	O
component	O
of	O
denial	O
and	O
avoiding	O
difficult	O
conversations	O
-	O
which	O
makes	O
conversations	O
difficult,	O
but	O
was	O
not	O
considered	O
justification	O
for	O
declaring	O
lack	O
of	O
capacity.	O
She	O
was	O
discharged	O
home	O
with	O
___.	O
She	O
has	O
existing	O
home	B-Has_carers
services.	B-Has_carers
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Zolpidem	O
Tartrate	O
10	O
mg	O
PO	O
QHS	O
2.	O
Diltiazem	O
Extended-Release	O
240	O
mg	O
PO	O
DAILY	O
3.	O
TraMADol	O
50	O
mg	O
PO	O
Q8H:PRN	O
Pain	O
-	O
Moderate	O
4.	O
Lisinopril	O
40	O
mg	O
PO	O
DAILY	O
5.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
Constipation	B-Constipation
-	O
First	O
Line	O
6.	O
Baclofen	O
10	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Lidocaine	O
5%	O
Patch	O
1	O
PTCH	O
TD	O
QAM	O
RX	O
*lidocaine	O
[Lidoderm]	O
5	O
%	O
apply	O
to	O
back	O
QAM	O
Disp	O
#*30	O
Patch	O
Refills:*0	O
2.	O
OxyCODONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q4H:PRN	O
Pain	O
-	O
Moderate	O
RX	O
*oxycodone	O
5	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
every	O
eight	O
(8)	O
hours	O
Disp	O
#*20	O
Tablet	O
Refills:*0	O
3.	O
Baclofen	O
10	O
mg	O
PO	O
DAILY	O
4.	O
Diltiazem	O
Extended-Release	O
240	O
mg	O
PO	O
DAILY	O
5.	O
Lisinopril	O
40	O
mg	O
PO	O
DAILY	O
6.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
Constipation	B-Constipation
-	O
First	O
Line	O
7.	O
TraMADol	O
50	O
mg	O
PO	O
Q8H:PRN	O
Pain	O
-	O
Moderate	O
8.	O
Zolpidem	O
Tartrate	O
10	O
mg	O
PO	O
QHS	O
Discharge	O
Disposition:	O
Home	B-Has_carers
With	B-Has_carers
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Urosepsis	O
Likely	O
pancreatic	O
CA	O
Pelvic	O
Mass	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	O
requires	O
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
It	O
was	O
a	O
pleasure	O
caring	O
for	O
you	O
at	O
___.	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
worsening	O
abdominal	O
pain	O
and	O
swelling.	O
You	O
were	O
found	O
to	O
have	O
"sepsis",	O
significant	O
bacterial	O
infection	B-Urinary_tract_infection
arising	O
from	O
the	O
urinary	B-Urinary_tract_infection
system.	O
You	O
were	O
treated	O
with	O
antibiotics	O
with	O
significant	O
improvement.	O
You	O
requested	O
a	O
second	O
opinion	O
of	O
multiple	O
masses	O
in	O
your	O
abdomen.	O
CAT	O
scan	O
showed	O
signs	O
of	O
cancer	O
in	O
your	O
pelvis	O
and	O
pancreas	O
You	O
were	O
seen	O
by	O
cancer	O
specialists,	O
gynecologists,	O
radiologists.	O
You	O
under	O
went	O
multiple	O
diagnostic	O
tests,	O
including	O
peritoneal	O
fluid	O
removal	O
x	O
3,	O
ultrasound	O
guided	O
biopsy	O
of	O
an	O
abdominal	O
(omental)	O
mass,	O
and	O
endoscopic	O
ultrasound	O
with	O
biopsy.	O
These	O
tests	O
did	O
not	O
yield	O
a	O
good	O
sample	O
to	O
identify	O
an	O
existing	O
cancer.	O
The	O
mass	O
in	O
the	O
pancreas	O
has	O
a	O
lot	O
of	O
necrotic	O
content	O
(non-viable	O
cells)	O
and	O
thus	O
can	O
account	O
for	O
why	O
the	O
biopsy	O
did	O
not	O
reveal	O
an	O
adequate	O
sample.	O
However,	O
given	O
its	O
location,	O
we	O
believe	O
that	O
the	O
next	O
best	O
step	O
would	O
be	O
to	O
do	O
a	O
repeat	O
endoscopic	O
ultrasound	O
procedure	O
next	O
week.	O
You	O
will	O
be	O
notified	O
by	O
the	O
___	O
team	O
regarding	O
the	O
exact	O
timing	O
for	O
this.	O
As	O
discussed,	O
the	O
suspicion	O
for	O
cancer	O
is	O
high	O
given	O
the	O
appearance	O
of	O
the	O
mass	O
on	O
ultrasound	O
and	O
CT	O
scan,	O
elevated	O
cancer	O
markers,	O
and	O
the	O
evidence	O
of	O
invasion	O
of	O
surrounding	O
vessels	O
(in	O
the	O
pancreas).	O
Finding	O
the	O
exact	O
cancer	O
type	O
(assuming	O
this	O
is	O
indeed	O
the	O
case)	O
would	O
be	O
crucial	O
to	O
determine	O
what	O
is	O
and	O
what	O
is	O
not	O
feasible.	O
(For	O
example,	O
surgery,	O
chemotreatments,	O
etc..).	O
We	O
wish	O
you	O
quick	O
recovery	O
and	O
good	O
health.	O
Your	O
___	O
Team.	O
Followup	O
Instructions:	O
___	O

